<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04813822</url>
  </required_header>
  <id_info>
    <org_study_id>FHP-2021-2-26</org_study_id>
    <nct_id>NCT04813822</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Efficacy and Safety of Miconazole Nitrate + Domiphen Bromide Vaginal Cream in the Treatment of Subjects With Acute Vulvovaginal Candidiasis</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Miconazole Nitrate 2% + Domiphen Bromide Vaginal Cream in the Treatment of Subjects With Acute Vulvovaginal Candidiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aesculape CRO Belgium BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aesculape CRO Belgium BV</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicentre, three-arm, double-blind, randomized controlled, parallel-group,&#xD;
      comparative phase II clinical trial to evaluate miconazole nitrate 2% + domiphen bromide&#xD;
      vaginal cream in subjects with acute vulvovaginal candidiasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Females aged 18-50 years with a clinical diagnosis of an acute VVC episode at Screening Visit&#xD;
      will be randomly assigned to either miconazole nitrate 2% + low or high dose of domiphen&#xD;
      bromide vaginal cream or to the comparator product Gyno-Daktarin® vaginal cream (miconazole&#xD;
      nitrate 2%). The creams will be applied for 7 days and subjects will be followed up for 12&#xD;
      weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects with clinical cure</measure>
    <time_frame>First follow-up visit (Day 15)</time_frame>
    <description>Resolution of the VVC signs and symptoms that were present at Screening Visit (Baseline)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of subjects with mycological eradication</measure>
    <time_frame>First follow-up visit (Day 15)</time_frame>
    <description>A culture negative vaginal swab for growth of baseline Candida species</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of subjects with overall therapeutic success</measure>
    <time_frame>First follow-up visit (Day 15)</time_frame>
    <description>Achievement of both clinical cure and mycological eradication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with clinical cure</measure>
    <time_frame>First follow-up visit through Week 12</time_frame>
    <description>Resolution of the VVC signs and symptoms that were present at Screening Visit (Baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with mycological eradication</measure>
    <time_frame>First follow-up visit through Week 12</time_frame>
    <description>A culture negative vaginal swab for growth of baseline Candida species at Day 15, a culture and PCR negative vaginal swab for growth of baseline Candida species on the Other follow-up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with overall therapeutic success</measure>
    <time_frame>First follow-up visit through Week 12</time_frame>
    <description>Achievement of both clinical cure and mycological eradication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in vulvovaginitis symptom questionnaire total score</measure>
    <time_frame>Through Week 12</time_frame>
    <description>VSQ: Vulvovaginal symptoms questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the EQ-5D questionnaire total score</measure>
    <time_frame>Through Week 12</time_frame>
    <description>EQ-5D: health-related quality of life questionnaire</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Acute Vulvovaginal Candidiasis</condition>
  <arm_group>
    <arm_group_label>Miconazole Nitrate 2% + Domiphen Bromide Low Dose Vaginal Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The content of one applicator (5 g cream) is administered intravaginally once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Miconazole Nitrate 2% + Domiphen Bromide High Dose Vaginal Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The content of one applicator (5 g cream) is administered intravaginally once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gyno-Daktarin® Vaginal Cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The content of one applicator (5 g cream) is administered intravaginally once daily for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miconazole Nitrate 2% + Domiphen Bromide Low Dose</intervention_name>
    <description>Dosage 1</description>
    <arm_group_label>Miconazole Nitrate 2% + Domiphen Bromide Low Dose Vaginal Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miconazole Nitrate 2% + Domiphen Bromide High Dose</intervention_name>
    <description>Dosage 2</description>
    <arm_group_label>Miconazole Nitrate 2% + Domiphen Bromide High Dose Vaginal Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miconazole Nitrate 2%</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>Gyno-Daktarin® Vaginal Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion criteria:&#xD;
&#xD;
          1. Subjects must be generally healthy, non-pregnant females, 18-50 years of age at&#xD;
             Screening Visit.&#xD;
&#xD;
          2. Subjects must have an acute VVC episode at Screening Visit, defined as a total signs&#xD;
             and symptoms score of ≥3 and a positive KOH wet mount preparation or Gram stain from a&#xD;
             vaginal smear revealing filamentous hyphae/pseudohyphae and/or budding yeast cells.&#xD;
&#xD;
        Main exclusion criteria :&#xD;
&#xD;
          1. Subjects with the presence of concomitant vulvovaginitis caused by other pathogens at&#xD;
             Screening Visit, or any other infection that requires antibiotic treatment.&#xD;
&#xD;
          2. Subjects with visible condylomas on vulvovaginal examination at Screening Visit.&#xD;
&#xD;
          3. Subjects with the presence or a history of another vaginal or vulvar condition(s) that&#xD;
             in the Investigator's opinion would confound the interpretation of the clinical&#xD;
             response.&#xD;
&#xD;
          4. Subjects with a history of cervical cancer.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Paul Deslypere, dr</last_name>
    <phone>+32492735931</phone>
    <email>jpdeslypere@aesculape.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miconazole</mesh_term>
    <mesh_term>Clotrimazole</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

